iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/39102007/
Neuroplasticity in Parkinson's disease - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;131(11):1329-1339.
doi: 10.1007/s00702-024-02813-y. Epub 2024 Aug 5.

Neuroplasticity in Parkinson's disease

Affiliations
Review

Neuroplasticity in Parkinson's disease

Bogdan Ovidiu Popescu et al. J Neural Transm (Vienna). 2024 Nov.

Abstract

Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, affecting millions of people and rapidly increasing over the last decades. Even though there is no intervention yet to stop the neurodegenerative pathology, many efficient treatment methods are available, including for patients with advanced PD. Neuroplasticity is a fundamental property of the human brain to adapt both to external changes and internal insults and pathological processes. In this paper we examine the current knowledge and concepts concerning changes at network level, cellular level and molecular level as parts of the neuroplastic response to protein aggregation pathology, synapse loss and neuronal loss in PD. We analyse the beneficial, compensatory effects, such as augmentation of nigral neurons efficacy, as well as negative, maladaptive effects, such as levodopa-induced dyskinesia. Effects of physical activity and different treatments on neuroplasticity are considered and the opportunity of biomarkers identification and use is discussed.

Keywords: AMPA; BDNF; Biomarkers; Dopamine; NMDA; Neuroplasticity; Parkinson’s disease.

PubMed Disclaimer

Similar articles

References

    1. Agosta F, Gatti R, Sarasso E, Volonté MA, Canu E, Meani A, Sarro L, Copetti M, Cattrysse E, Kerckhofs E, Comi G, Falini A, Filippi M (2017) Brain plasticity in Parkinson’s disease with freezing of gait induced by action observation training. J Neurol 264(1):88–101. 10.1007/s00415-016-8309-7 - PubMed
    1. Ahlskog JE (2011) Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 77(3):288–294. 10.1212/WNL.0b013e318225ab66 - PMC - PubMed
    1. Ahlskog JE (2018) Aerobic exercise: evidence for a direct brain effect to slow parkinson disease progression. Mayo Clin Proc 93(3):360–372. 10.1016/j.mayocp.2017.12.015 - PubMed
    1. Albin RL, Leventhal DK (2017) The missing, the short, and the long: Levodopa responses and dopamine actions. Ann Neurol 82(1):4–19. 10.1002/ana.24961 - PMC - PubMed
    1. Anderson RW, Farokhniaee A, Gunalan K, Howell B, McIntyre CC (2018) Action potential initiation, propagation, and cortical invasion in the hyperdirect pathway during subthalamic deep brain stimulation. Brain Stimul 11(5):1140–1150. 10.1016/j.brs.2018.05.008 - PMC - PubMed

LinkOut - more resources